Ozempic Tracker App
Track Your Semaglutide Protocol
Ozempic (semaglutide 0.25–2 mg weekly) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes that also produces clinically significant weight loss. The SUSTAIN-6 and STEP trials confirmed both glycaemic and cardiometabolic benefits. Shotlee is the free app for logging every weekly injection, tracking your weight trend, and monitoring side effects throughout your dose escalation.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free to Use
What Is Ozempic (Semaglutide)?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in December 2017 for the treatment of type 2 diabetes in adults. It works by mimicking the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and activating hypothalamic satiety centres to reduce appetite.
Ozempic is administered as a once-weekly subcutaneous injection starting at 0.25 mg for tolerability, escalating to 0.5 mg, 1 mg, and up to 2 mg as needed. While approved for T2D, Ozempic is widely recognised for producing substantial weight loss — the same molecule at 2.4 mg weekly was approved as Wegovy for obesity. The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in MACE in high-CV-risk T2D patients.
Ozempic vs Wegovy: Same Molecule, Different Indication
Both Ozempic and Wegovy contain semaglutide. Ozempic is approved for type 2 diabetes (max 2 mg). Wegovy is approved for obesity at a higher 2.4 mg dose. Track either or both in Shotlee.
Ozempic Dose Escalation Schedule
0.25 mg/week
Weeks 1–4
Starting dose to build GI tolerance. Not a therapeutic glycaemic dose — this is a tolerability step.
0.5 mg/week
Weeks 5–8
First therapeutic maintenance dose. Adequate glycaemic control achieved here for many patients.
1 mg/week
Weeks 9+
Standard maintenance dose for enhanced HbA1c reduction and weight loss effect.
2 mg/week
As prescribed
Maximum approved dose for additional glycaemic and weight benefit. SUSTAIN-10 showed superior HbA1c at 2 mg.
What to Track in Shotlee
Dose Log
Record every weekly injection: date, dose, pen lot number, and injection site (abdomen, thigh, arm).
Weekly Weight
Track body weight weekly to see your personal dose-response curve against the STEP-1 14.9% benchmark.
Side Effects
Log nausea, GI symptoms, and fatigue with severity ratings to guide your dose escalation decisions.
Lab Results
Save HbA1c, fasting glucose, and lipid results from each clinic visit to track biomarker improvements.
Measurements
Waist and hip circumference track fat loss independently of scale weight during escalation phases.
Hunger Levels
Daily appetite ratings reveal how well each dose level is controlling cravings between injections.
Clinical Trial Results (SUSTAIN & STEP Programs)
Mean weight loss (STEP-1)
14.9%
Mean body weight reduction at 68 weeks with semaglutide 2.4 mg in STEP-1 (obesity population).
HbA1c reduction (SUSTAIN-6)
-1.5%
Mean HbA1c reduction with semaglutide 1 mg vs -0.9% placebo in SUSTAIN-6 at 104 weeks.
MACE reduction (SUSTAIN-6)
-26%
Relative reduction in major adverse CV events with semaglutide vs placebo in high-risk T2D patients.
How to Track Your Ozempic Protocol
Set a baseline: log your starting weight, waist measurement, and latest HbA1c before your first dose
Record every injection: date, dose, pen lot number, injection site, and any site reactions
Log weekly weight at the same time and day each week to build a clean dose-response curve
Track side effects with severity and timing so your prescriber can optimise your dose escalation
Enter HbA1c and glucose results from each clinic visit to measure your glycaemic response over time
Ozempic vs Wegovy: Key Differences
| Feature | Ozempic | Wegovy |
|---|---|---|
| Approved indication | Type 2 diabetes | Obesity / weight management |
| Maximum dose | 2 mg/week | 2.4 mg/week |
| Active ingredient | Semaglutide | Semaglutide |
| Dosing frequency | Once weekly | Once weekly |
| Key trial | SUSTAIN-6 (CV outcomes) | STEP-1 (weight loss) |
| Insurance coverage | T2D indication | Obesity criteria |
Protocol FAQs
Log each weekly injection in Shotlee with the dose (0.25–2 mg), injection site, and any side effects. Shotlee keeps a complete timeline of your protocol history and reminds you when your next weekly dose is due.
Yes. Shotlee supports tracking multiple medications simultaneously, including combination protocols such as Ozempic with metformin, insulin, or other diabetes medications.
Both contain semaglutide. Ozempic (max 2 mg) is approved for type 2 diabetes. Wegovy (max 2.4 mg) is approved for obesity/weight management. Shotlee tracks both medications with full dose support.
Most patients see meaningful weight loss beginning at week 8–12. Maximum effect in the STEP-1 trial occurred around week 68 with 14.9% mean weight loss. Track weekly in Shotlee to see your personal response curve.
Yes. Log your pen lot number, start date, and injection site. Shotlee helps you rotate between abdomen, thigh, and upper arm to prevent lipodystrophy.
References
- [1]Clinical TrialWilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384(11):989-1002.
- [2]Clinical TrialMarso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM. 2016;375(19):1834-1844.
- [3]FDAFDA. "Ozempic (semaglutide) injection label." NDA 209637. 2017.
Track Your Ozempic Protocol in Shotlee
Free dose logs, weekly weight trends, side effect tracking — all in one place.
🚀 Use Shotlee for Free